Clinical Trial Update: First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 [Phase 1]

View source ↗

Summary

A first-in-man Phase 1 trial evaluating biodistribution, safety, and the recommended dose of a radiolabeled anti-FZD10 monoclonal antibody in synovial sarcoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Synovial Sarcoma

Drugs mentioned

• Radiolabeled anti-FZD10 monoclonal antibody

Snippet

Sponsor: Centre Leon Berard | Conditions: Sarcoma, Synovial | Phase 1 | Status: TERMINATED